Pembrolizumab (MK-3475) Versus Placebo Following Surgery and Radiation in Participants With Locally Advanced Cutaneous Squamous Cell Carcinoma (MK-3475-630/KEYNOTE-630)

Active:	No
Cancer Type:	Skin Cancer (Non-Melanoma) Unknown Primary	NCT ID:	NCT03833167
Trial Phases:	Phase III	Protocol IDs:	3475-630 (primary) KEYNOTE-630 2018-001974-76 NCI-2019-01629 MK-3475-630
Eligibility:	18 Years and older, Male and Female	Study Type:	Treatment
Study Sponsor:	Merck Sharp & Dohme LLC
NCI Full Details:	http://clinicaltrials.gov/show/NCT03833167

Summary

This is a randomized, double-blind, study that compares pembrolizumab (MK-3475) with
placebo given as adjuvant therapy in participants with high-risk locally advanced
cutaneous squamous cell carcinoma (LA cSCC) that have undergone surgery with curative
intent in combination with radiotherapy. The primary hypothesis is that pembrolizumab is
superior to placebo in increasing recurrence free survival (RFS).

Treatment Sites in Georgia

Winship Cancer Institute of Emory University
1365 Clifton Road NE
Building C
Atlanta, GA 30322
404-778-5180
winshipcancer.emory.edu

**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts... Click here to learn more about clinical trials.